Impact of Reimbursement for Biomarker Testing on Clinical Practice
Video Categories: PMO Interview with the Innovator Series: Volume 12 and Video LibraryDrs. Geoffrey Oxnard and Lauren Ritterhouse deliberate on ways reimbursement issues are impacting clinical practice, particularly CMS’s “14-Day Rule.”
Related Videos

Financial Constraints to Molecular Biomarker Testing
Drs. David Rimm and Roy Herbst discuss the challenges of reimbursement by payers and the costs to pathology department of molecular biomarker testing, especially immunohistochemistry and DNA testing.
Serotonin and Carcinoid Tumors
Hal Gerstein, MD, details this neurotransmitter’s role in the development of carcinoid tumors and carcinoid syndrome.